Visit https://www.peervoice.com/VYU860 to view the entire programme with slides. After completing “Novel Therapies for Patients With DLBCL: What Does the Future Hold?”, participants will be able to: Explain the rationale for novel therapeutic options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Evaluate the risk-benefit profiles of current and emerging therapies for the management of R/R DLBCL; and Incorporate available data on the use of novel anti-CD19 antibody strategies to treat R/R DLBCL into clinical practice.